A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria
Phase 3
Completed
NCT04058158
| Condition | Paroxysmal Nocturnal Hemoglobinuria |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Samsung Bioepis Co., Ltd. |
|---|
| Status | Completed |
|---|
| Enrollment | 50 participants |
|---|
| Interventions | SB12 (proposed eculizumab biosimilar), Soliris (eculizumab) |
|---|
| Start date | Aug 7, 2019 |
|---|
| Completion date | Sep 21, 2021 |
|---|
| Results posted | Mar 26, 2024 |
|---|
Summary
This is a randomised Phase III, double-blind, multicentre, cross-over study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB12 and Soliris® in subjects with PNH.
Lactate Dehydrogenase (U/L) at Week 26
Week 26 · U/L
| SB12 | 284.20 ± 456.73 U/L |
|---|
| Soliris | 249.72 ± 103.67 U/L |
|---|
| Least squares mean difference | 34.48 (95% CI -47.66–116.62) |
|---|
Time-adjusted AUEC of LDH From Week 14 to Week 26 and From Week 40 to Week 52
From Week 14 to Week 26 and from Week 40 to Week 52 · U/L
| SB12 | 279.65 ± 325.37 U/L |
|---|
| Soliris | 258.73 ± 95.09 U/L |
|---|
| Ratio of geometric least squares mean | 1.08 (95% CI 0.95–1.23) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.